All In Biotech

Drug Trial Radar · NCT05806164

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

432

Planned (sponsor's estimate)

Start

Jun 6, 2023

Primary completion

Aug 30, 2026

Study completion Aug 1, 2030

Sponsor

Lead sponsor
Women and Infants Hospital of Rhode IslandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of New Mexico; University of Alabama at Birmingham; University of California, San Diego; Howard University; Brown University; Patient-Centered Outcomes Research Institute
First posted
Apr 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity. The study will also have a long-term follow-up component (prospective cohort) including 346 participants from the parent trial to describe treatment continuation, treatment efficacy, patient direct costs and other secondary outcomes up to 5 years after treatment.

Conditions

  • Urgency Urinary Incontinence

Interventions

  • Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]Drug

    The beta-agonist oral medication will be prescribed and dose adjusted per usual care.

  • OnabotulinumtoxinA 100 UNT [Botox]Drug

    OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in score Overactive Bladder Questionnaire-Symptom Bother Scale (OAB-q-SS) at 3 monthsTime frame: Baseline until 3 months
  2. Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General Questionnaire (FACIT-TS-G) at 3 monthsTime frame: 3 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California, San Diego

    San Diego, California

  • Howard University

    Washington D.C., District of Columbia

  • University of New Mexico

    Albuquerque, New Mexico

  • Women & Infants Hospital of Rhode Island

    Providence, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.